Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
OLMA Stock Chart & Stats
$28.77
$0.55(10.50%)
At close: 4:00 PM EST
$28.77
$0.55(10.50%)
Day’s Range― - ―
52-Week Range$2.86 - $36.26
Previous CloseN/A
Volume1.27M
Average Volume (3M)2.23M
Market Cap
$2.26B
Enterprise Value$514.84M
Total Cash (Recent Filing)$328.96M
Total Debt (Recent Filing)$4.48M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Mar 02, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding78,659,920
10 Day Avg. Volume1,283,679
30 Day Avg. Volume2,227,920
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)0.84
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.02K
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
$42.00Price Target Upside45.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Adjuvant Market Expansion OpportunityEvidence that oral SERDs can work in the adjuvant setting strengthens the case for palazestrant to expand into a much larger adjuvant market, making a pharma partnership and additional funding more commercially attractive.
Clinical Readthrough From Comparable TrialPositive pivotal results for a comparable oral SERD support a favorable readthrough to Olema's palazestrant programs, increasing confidence in outcomes for similar OPERA-02 trial designs.
Combination Therapy AdvantageUse of ribociclib in Olema's palazestrant combination may provide a clinical differentiation versus rival CDK4/6 pairings, potentially improving efficacy prospects in frontline ER positive breast cancer.
Bears Say
High Cash Burn And Financing RiskA relatively high annual cash burn raises the probability that Olema will need external financing or a partnership, which could dilute investors or slow program timelines.
Potential Analyst Conflict Of InterestBusiness relationships between the reporting firm and the company could introduce bias into published reports, reducing confidence in the objectivity of analyst recommendations.
Uncertainty About Combination ImpactQuestions persist on how adding a CDK4/6 inhibitor will influence head‑to‑head trial outcomes, creating execution risk for the combination strategy in pivotal studies.
Olema Pharmaceuticals News
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $2.86 and its highest was $36.26 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Olema Pharmaceuticals’s market cap is $2.26B.
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Mar 02, 2026 which is in 45 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on Nov 11, 2025. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.475 by -$0.015.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -0.52.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 78,659,920 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.475. Following the earnings report the stock price went down -5.862%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Currently, no hedge funds are holding shares in OLMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Olema Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.00 (45.99% Upside)
$42.00 (45.99% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
476.23%
12-Months-Change
Fundamentals
Return on Equity
-59.22%
Trailing 12-Months
Asset Growth
53.13%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
OLMA Stock 12 Month Forecast
Average Price Target
$42.00
▲(45.99% Upside)
Technical Analysis
Meiragtx Holdings
―
Arvinas Holding Company
―
Gossamer Bio
―
Keros Therapeutics
―
Compass Therapeutics
―
Ownership Overview
Currently, No data available
---